Figures & data
Figure 1. Study design.
Table 1. Anti-HBs antibody seropositivity rates and geometric mean concentrations from primary vaccination at infancy until year 20 for pooled groups with boosted and unboosted at year 5 (Long-term ATP cohort for immunogenicity)
Figure 2. Evolution of anti-HBs geometric mean concentrations in boosted and unboosted groups (LT-ATP immunogenicity cohort). Boosted group: Subjects who received booster dose at year 5 (month 60). Unboosted group: Subjects who did not receive the booster dose at year 5 (month 60). Note: At year 9 the results of only 10 subjects were included in the analysis- hence this time point should not be taken into account to assess the kinetic of the immune response. This limited number of subjects was due to logistic problems during the conduct of the study which resulted in fewer subjets being loaded into the database. From the commencement of primary vaccination until follow-up year 10, anti-HBs antibodies were measured using AUSAB RIA (Abbott Laboratories). *Assay change from year 11 until year 16: Antibodies were measured using AUSAB EIA (Abbott Laboratories, IL, USA). ^Assay change from year 17 until year 20: Antibodies were measured using an in-house validated ELISA.
Table 2. Anti-HBs seropositivity rates, percentage of subjects with antibody concentrations ≥ 10 mIU/ml and GMCs at the pre- and post-challenge dose time-point (long-term ATP cohort for immunogenicity) in the groups boosted and unboosted at year 5
Figure 3. Serum antibody concentrations at the pre- and post-challenge dose time-point (Long-term ATP cohort for immunogenicity) in the groups boosted and unboosted at year 5. Each box shows the median (horizontal line), quartile range (the box itself), and high (97.5%) and low (2.5%) (whiskers).
